Blackrock Future Health ETF

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Nanobiotix Reports 85.7% Response Rate for JNJ-1900 in Lung Cancer Trial Phase II

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Allworth Financial LP Increases Merck Holdings by 71.4%

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

Leerink Partners Raises Johnson & Johnson's Rating and Price Target

Amesite

InMed Pharmaceuticals

Meiwu Tech

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

MetaVia

Phoenix Asia

NextNRG

Co-Diagnostics

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

AVTX

TMED

ARKG

BMED

SBIO

IBBQ

Avalo Therapeutics, Inc. has seen its 12-month stock price target cut to $47.82, suggesting a potential upside of 144%. The average price target from 10 analysts has increased from $48.1 to $48.7, with estimates ranging from $35 to $62 per share. The consensus rating remains a "Buy" with 12 analysts recommending buys and none holding or selling. This information is based on the latest analyst forecasts and does not constitute investment advice.

TradingView

Avalo Therapeutics

SPDR S&P Biotech

T. Rowe Price Health Care ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Factset Research

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing a revenue of $19.7M and a net loss of $19.63M, reflecting a year-over-year decline in both metrics. The company achieved positive Phase 2 results for its drug abdakibart in treating hidradenitis suppurativa, supporting plans for Phase 3 trials. R&D and G&A expenses increased to prepare for pivotal trials, and the company completed a $405M follow-on offering to fund operations through 2029.

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

benzinga_article

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

StockTitan

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

Avalyn Pharma Inc. has set its IPO price at $18 per share for its upcoming trading on the Nasdaq under the ticker "AVLN" starting April 30, 2026. The company plans to offer 16.67 million shares, aiming for gross proceeds of $300 million, with the offering closing on May 1, 2026.

rttnews

iShares US Healthcare Providers

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Proshares UltraShort Nasdaq Biotech

Nasdaq

Avalyn Sets IPO Price At $18 Per Share

HEAL

FDHT

The mHealth market worldwide is on the rise driven by various factors such as the growing acceptance of mHealth solutions, a rise in cases of heart disease, and an increased awareness about mHealth devices in developing nations. As of April 27, 2026, in Portland, Oregon, the market is gaining traction with significant numbers of users and patients turning to mHealth applications for healthcare needs.

Unusual Whales

Global X HealthTech ETF

Fidelity Digital Health ETF

mHealth Market Size to Hit USD 370.7 billion, Globally, by 2032 at 18.0% CAGR: Allied Market Research

159837

Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO

RenaissanceCapital

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

BlackRock, Inc.

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

iShares Genomics Immunology and Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Morgan Stanley

Jefferies Financial

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO

Wall Street analysts have initiated coverage on several stocks, including Avalo Therapeutics Inc (NASDAQ:AVTX), which received a Market Outperform rating and a price target of $52 from Citizens analyst Jason Butler. Avalo shares closed at $17.76. Other notable initiations include PayPay Corp (NASDAQ:PAYP) with an Outperform rating and a price target of $26, and Atlas Critical Minerals Corp (NASDAQ:ATCX) with a Buy rating and a price target of $13.75. Analysts have changed their outlooks on various stocks, reflecting a mix of upgrades and downgrades.

Atlas Critical Minerals

PayPay

This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avalo Therapeutics insider Mittie Doyle sold 679 shares at $16.00 each, totaling $10,864, reducing her stake by 15.79% to 3,622 shares valued at approximately $57,952. The sale was part of a pre-arranged trading plan and disclosed to the SEC. Avalo's stock remained flat at $17.76, with a market cap of $404.75 million. Analysts have mixed ratings, with a consensus of "Moderate Buy" and an average price target of $42.25. Institutional investors hold 87.06% of the stock, reflecting strong interest in the company.

Market Beat

Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares

Today's whale alerts in the Health Care sector highlight significant trading activities. Notable options include BMY with a bullish put trade, AVTX with a bearish call trade, and LLY with a bullish call sweep. Other mentions are SLS, MRK, NVO, CNC, JNJ, and TMDX, showcasing various sentiments and expiration dates. These alerts can guide traders in identifying potential trading opportunities based on abnormal market activities.

Blackrock Future Health ETF(BMED.US)

Avalo Therapeutics, Inc. Stock 12‑Month Price Target Cut to $47.82, Implies 140% Upside

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

Avalyn Sets IPO Price At $18 Per Share